Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Magenta Therapeutics Raises USD52 Million in Series C Financing 12
Magenta Therapeutics Raises USD50 Million in Series B Financing 14
Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16
Partnerships 17
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17
Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18
Magenta Therapeutics Enters into Agreement with University of Minnesota 19
Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20
Licensing Agreements 21
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21
Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22
Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23
Equity Offering 24
Magenta Therapeutics Raises USD100 Million in IPO of Shares 24
Debt Offering 26
Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26
Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27
Magenta Therapeutics Inc – Key Competitors 28
Magenta Therapeutics Inc – Key Employees 29
Magenta Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Recent Developments 31
Financial Announcements 31
Aug 09, 2018: Magenta Therapeutics reports recent operational progress and second quarter 2018 financial results 31
Corporate Communications 32
Apr 09, 2018: Magenta Therapeutics Appoints Amy Ronneberg to its Board of Directors 32
Apr 06, 2018: Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors 33
Apr 03, 2018: Magenta Therapeutics announces departure of chief operating officer Bastiano Sanna, Ph.D. 34
Feb 21, 2018: Magenta Therapeutics Hires John Davis, MD, MPH, as Chief Medical Officer 35
Oct 24, 2017: Magenta Therapeutics Appoints Alison Lawton, Jeff Albers and Blake Byers to its Board of Directors 36
Legal and Regulatory 37
Sep 24, 2018: Magenta Therapeutics added to Russell 2000 and 3000 Indexes 37
Product News 38
12/11/2017: Magenta’s Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust Neutrophil and Immune Recovery in Two Phase II Clinical Studies 38
Dec 09, 2017: Magenta Therapeutics’ lead targeted antibody drug conjugate shows promising preclinical results for non-genotoxic conditioning for bone marrow transplant 39
05/10/2017: Magenta Therapeutics Announces New Clinical Data on its Lead Expansion Clinical Program, MGTA-456, Presented at American Society of Gene and Cell Therapy Annual Meeting 40
Clinical Trials 41
Apr 05, 2018: Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders 41
Nov 01, 2017: Magenta Therapeutics to Present Clinical Results and Preclinical Research at American Society of Hematology (ASH) Annual Meeting 42
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Magenta Therapeutics Raises USD52 Million in Series C Financing 12
Magenta Therapeutics Raises USD50 Million in Series B Financing 14
Magenta Therapeutics Raises USD48.5 Million in Series A Venture Financing 16
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 17
Magenta Therapeutics Enters into Development and Manufacturing Agreement with Bachem Americas 18
Magenta Therapeutics Enters into Agreement with University of Minnesota 19
Magenta Therapeutics Enters into Partnership with Be The Match BioTherapies 20
Magenta Therapeutics Enters into Licensing Agreement with Novartis for MGTA-456 21
Magenta Therapeutics Enters into a Licensing Agreement with Trianni 22
Magenta Therapeutics Enters into Licensing Agreement with President and Fellows of Harvard College 23
Magenta Therapeutics Raises USD100 Million in IPO of Shares 24
Magenta Therapeutics Raises USD6.5 Million in Private Placement of 6% Convertible Promissory Notes 26
Magenta Therapeutics Raises USD0.5 Million in Private Placement of Convertible Promissory Notes 27
Magenta Therapeutics Inc, Key Competitors 28
Magenta Therapeutics Inc, Key Employees 29
List of Figures
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Magenta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer